Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Matinas BioPharma received a notice from NYSE American on August 31, 2026, stating the company is not in compliance with continued listing standards due to stockholders' equity of $1.8 million (below the required $2.0 million threshold) and losses in five consecutive fiscal years. The company submitted a compliance plan accepted by NYSE American with a deadline of October 2, 2027. Shares will continue trading during the plan period, but delisting proceedings may be initiated if compliance is not achieved.